Skip to main content

Table 3 Clinical and biomarker characteristics obtained at baseline and follow-up of all available patients

From: The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial

Characteristic   No. = 133
Female gender (%)   87 (65)
Age (years)   53 (14)
RF positivity (%)   87 (65)
Baseline DAS28   5.6 (1.0)
Baseline joint damage   0.0 (0.0-0.0)
EULAR good responders (%)   50 (38)
EULAR moderate responders (%)   58 (44)
EULAR no responders (%)   24 (18)
Time-averaged DAS28   3.0 (0.9)
Radiographic progression rate   1.0 (0.0-3.4)
C2C (ng/ml) Baseline 90 (71-124)
  1 yr 86 (70-109)
C1,2C (ng/ml) Baseline 359 (286-427)
  1 yr 349 (269-415)
CS846 (ng/ml) Baseline 100 (68-155)
  1 yr 113 (69-183)
CPII (ng/ml) Baseline 335 (207-551)
  1 yr 436 (220-613)
  1. Mean (SD) is shown for age and (baseline and time-averaged) DAS28; median (IQR) is shown for all other (non-normally distributed) continuous variables. For all categoric variables, number (%) of patients is shown. The EULAR response was determined after 6 months of treatment; time-averaged DAS28 and radiographic progression rate were calculated over 5 years of treatment; all other variables were determined at baseline unless otherwise stated. RF, rheumatoid factor; DAS28, disease activity score based on 28 joints.